Aurobindo gets FTC nod for Lannett Co acquisition

Aurobindo Pharma's US arm received Federal Trade Commission approval for its $250 million acquisition of Lannett Company. The deal, expected to close by June 2026, strengthens Aurobindo's complex generics and controlled substances portfolio and adds Lannett's Indiana manufacturing facility. The acquisition is projected to immediately boost earnings per share.